Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Status:
Suspended
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in
diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can
attach to tumor cells and make them more visible using a special camera during surgery, which
may help surgeons better distinguish tumor cells from normal brain tissue and identify small
tumors that cannot be seen using current imaging methods.